Last reviewed · How we verify
Two-week course of radiation
Ionizing radiation damages cancer cell DNA to inhibit tumor growth and induce cell death.
Ionizing radiation damages cancer cell DNA to inhibit tumor growth and induce cell death. Used for Solid tumors (specific indication not specified in source).
At a glance
| Generic name | Two-week course of radiation |
|---|---|
| Also known as | experimental arm |
| Sponsor | Jong Hoon Lee |
| Drug class | Radiation therapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Radiation therapy delivers high-energy particles or photons that create double-strand breaks in DNA, triggering apoptosis in rapidly dividing cancer cells. A two-week course typically represents a hypofractionated or abbreviated regimen designed to balance efficacy with reduced treatment burden and toxicity compared to conventional multi-week protocols.
Approved indications
- Solid tumors (specific indication not specified in source)
Common side effects
- Fatigue
- Skin erythema/dermatitis
- Nausea
- Hair loss (alopecia)
- Mucositis
Key clinical trials
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (EARLY_PHASE1)
- Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors
- Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies (NA)
- New MRI Biomarkers in Head and Neck Cancers
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- Efficacy and Safety of Qibei Jiedu Formula for Preventing and Managing Acute Radiation Dermatitis in Breast Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Two-week course of radiation CI brief — competitive landscape report
- Two-week course of radiation updates RSS · CI watch RSS
- Jong Hoon Lee portfolio CI